Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

--------------- ------------------------------------------------------------------------- Weighted average shares outstanding (000's) - basic and diluted 85,015 85,015 ------------------------------------------------------------------------- ------------------------------------------------------------------------- a. Amounts accrued for costs incurred, and potential future costs, related to our offer to accept returns of Contour Threads brand product as part of consolidation and discontinuation of the Contour Threads brand name, coincident with the launch of our Quill SRS brand name. b. Non-recurring, non-operating license revenue. c. Severances and reorganization costs. In 2007, change in estimate of accounting for excess and obsolete inventory resulting from the alignment during the second quarter of 2007 of inventory policies across our various manufacturing operations. d. Research and development adjustments: --------------------------------------------------------------------- Year-ended Year-ended Dec 31, 2008 Dec 31, 2007 ------------- ------------- Stock-based compensation (795) (1,665) License fees due to licensors related to non-recurring license revenue - (419) Termination and reorganization costs (3,302) (849) Non-recurring supply / distribution agreement termination costs (500) (899) Non-recurring research and development expenses and intellectual property license agreement. (938) (750)
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... N.J. , Jan. 27 Covance Inc. (NYSE: ... 31, 2009 of $0.64 per diluted share.  For the ... inclusive of $0.10 per share in gains related to sales ... the third quarter.  Excluding the gains on sales and the tax item, ...
... ... leaders at Biomanufacturing Summit in La Jolla, California January 26th and 27th, 2010. ... Fort Collins, CO ... InVitria’s products enable its customers to optimize their biomanufacturing process from the cell bank ...
... , , , , ... January 27 Jubilant Biosys,Ltd., a subsidiary of Jubilant ... Pa. , U.S.A., announced today that they have,expanded their drug ... stage milestone. , The year-old partnership ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17InVitria Sponsors 2010 Biomanufacturing Summit 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 2Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone 3
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... commerce market, reports on the recent success of the Wocket™ smart wallet ... Wocket smart wallet was named as one of the "11 Hot ... "5 Best Products Launched At CES So Far" by Newseveryday.com and "The ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... mother,s diet may be able to interact with the genes ... of birth defect according to research funded by the Wellcome ... in the journal Human Molecular Genetics , suggests that ... pregnancy could be inadvertently putting the health of their offspring ...
... mechanism by which a herpes virus invades cells has remained ... viruses. New research funded by the National Institutes of Health ... Structural & Molecular Biology reveals the unusual structure of ... cells. This detailed map of a key piece of the ...
... 6, 2010 Investigators at the Translational Genomics Research Institute ... patients who no longer respond to conventional chemotherapy. A ... of the journal Gynecologic Oncology describes how the ... to incorporate into therapies for women with ovarian cancer. ...
Cached Biology News:Maternal diet and genes interact to affect heart development 2Maternal diet and genes interact to affect heart development 3Map of herpes virus protein suggests a new drug therapy 2TGen finds protein inhibitor revives chemotherapy for ovarian patients 2TGen finds protein inhibitor revives chemotherapy for ovarian patients 3
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: